STOCK TITAN

CPIX insider holdings reach 292,595 shares after October buys

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cumberland Pharmaceuticals (CPIX) director reported a series of open‑market purchases executed automatically under a Rule 10b5-1 trading plan adopted on November 14, 2024. The transactions occurred on multiple trading days from October 1 to October 31, 2025, with 68 shares acquired each day at prices generally in the $3.14–$3.63 range.

Following these purchases, the reporting person’s directly held stake was 292,595 shares as of October 31, 2025. The filing indicates it was made by a single reporting person serving as a Director, with all holdings shown as Direct (D).

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Krogulski Kenneth

(Last) (First) (Middle)
1600 WEST END AVE., SUITE 1300

(Street)
NASHVILLE TN 37203

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 L V 68(1) A $3.31 291,099 D
Common Stock 10/02/2025 L V 68(1) A $3.28 291,167 D
Common Stock 10/03/2025 L V 68(1) A $3.25 291,235 D
Common Stock 10/06/2025 L V 68(1) A $3.14 291,303 D
Common Stock 10/07/2025 L V 68(1) A $3.19 291,371 D
Common Stock 10/08/2025 L V 68(1) A $3.63 291,439 D
Common Stock 10/09/2025 L V 68(1) A $3.56 291,507 D
Common Stock 10/10/2025 L V 68(1) A $3.59 291,575 D
Common Stock 10/13/2025 L V 68(1) A $3.54 291,643 D
Common Stock 10/14/2025 L V 68(1) A $3.35 291,711 D
Common Stock 10/15/2025 L V 68(1) A $3.37 291,779 D
Common Stock 10/16/2025 L V 68(1) A $3.49 291,847 D
Common Stock 10/17/2025 L V 68(1) A $3.48 291,915 D
Common Stock 10/20/2025 L V 68(1) A $3.52 291,983 D
Common Stock 10/21/2025 L V 68(1) A $3.61 292,051 D
Common Stock 10/22/2025 L V 68(1) A $3.62 292,119 D
Common Stock 10/23/2025 L V 68(1) A $3.44 292,187 D
Common Stock 10/24/2025 L V 68(1) A $3.51 292,255 D
Common Stock 10/27/2025 L V 68(1) A $3.49 292,323 D
Common Stock 10/28/2025 L V 68(1) A $3.28 292,391 D
Common Stock 10/29/2025 L V 68(1) A $3.26 292,459 D
Common Stock 10/30/2025 L V 68(1) A $3.29 292,527 D
Common Stock 10/31/2025 L V 68(1) A $3.39 292,595 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.
Remarks:
Kenneth J. Krogulski by /s/ John Hamm as attorney-in-fact 10/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did CPIX disclose on Form 4?

A Director reported daily automatic purchases of 68 shares each trading day in October 2025 under a Rule 10b5-1 plan.

What prices were paid for the CPIX shares?

Reported prices for the daily 68‑share purchases were generally between $3.14 and $3.63.

What are the director’s CPIX holdings after these transactions?

Direct beneficial ownership was 292,595 shares as of October 31, 2025.

Was this trading under a 10b5-1 plan?

Yes. The purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.

How many reporting persons filed this Form 4 for CPIX?

It was filed by one reporting person.

Is the ownership reported as direct or indirect?

The filing lists ownership as Direct (D).
Cumberland Pharmaceuticals Inc

NASDAQ:CPIX

CPIX Rankings

CPIX Latest News

CPIX Latest SEC Filings

CPIX Stock Data

61.62M
8.73M
41.57%
24.77%
0.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE,